Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy
Research highlights
► We evaluated efficacy and safety of Hizentra® in primary immunodeficiency patients. ► Patients received weekly SCIG infusions at doses equivalent to previous treatment. ► IgG levels were maintained or increased with treatment. ► The annualized rate of all infections was 5.18 per patient. ► No serious treatment-related adverse events were reported.
Keywords
Cited by (0)
- 1
On behalf of the investigators. Germany: M. Borte, Municipal Hospital “St. Georg” GmbH Leipzig and Academic Teaching Hospital of the University of Leipzig, Leipzig (5 patients), W. Mannhardt-Laakmann, Universitäts-Kinderklinik der Johannes Gutenberg Universität, Mainz (2 patients), H. H. Peter, Universitätsklinikum Freiburg, Freiburg (3 patients), V. Wahn, Charité Campus Virchow-Klinikum, Berlin (4 patients); France: M. Debré, Hôpital Necker—Enfants malades, Paris (2 patients); Poland: E. Bernatowska, Child Health Institute, Warsaw (8 patients); Romania: V. Cristea, Clinica Medicala III, Cluj-Napoca (5 patients), M. Serban, Clinica III Pediatrie “Louis Turcanu”, Temesvar (5 patients); Spain: J. de Gracia, Hospital Vall d'Hebron, Barcelona (7 patients), T. González Quevedo, Hospitales Universitarios Virgen del Rocío, Sevilla (3 patients); Sweden: A. Fasth, The Queen Silvia Children's Hospital, Gothenburg (1 patient); Switzerland: A. Helbling, University Hospital Inselspital, Berne (2 patients); United Kingdom: B. Grimbacher, Royal Free Hospital and University College Medical School, London (2 patients), S. Jolles, University Hospital of Wales, Cardiff (1 patient), H. Longhurst, The Royal London Hospital, London (1 patient).